Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic

•Careful selection of NMOSD immunotherapy is critical during the COVID-19 pandemic.•Selective B-cell depletion may be safer than non-selective lymphocyte depletion.•Complement or IL-6 inhibitors may be safer than cell-depleting agents.•The effect on future SARS-CoV-2 vaccines should be considered.•Subcutaneous agents carry less exposure risk than intravenous agents.